September quarter profit rises 33%; first interim dividend of Rs 0.50 declared

Revenue Growth 20pctPat Growth 25pctNegative Operating CashflowResults RestatedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.0%Reaction day

₹418.95

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%+2.2% vs market

Pharmaceuticals peers, median of 173sector+2.0%+2.0% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.0+1.7+2.2+2.0+2.0

Next day

+2.6+1.8+0.8+2.6-0.0

+2.6+2.5+0.2+2.7-0.1

-2.1pendingpending+2.0-4.2

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved unaudited six-month results for 30 September 2026. In the September quarter, group net sales rose 50% to Rs 4,708.40 lakh and profit attributable to shareholders rose 33% to Rs 659.68 lakh. The auditor found no material issue. A first interim dividend of Rs 0.50 per share was declared, with 30 October 2026 as the record date. Group operating cash flow was negative Rs 30 lakh; prior figures were regrouped or restated.

Likely market impact

Strong quarterly growth and the first interim dividend support sentiment, but negative group operating cash flow needs monitoring.